🎉 Great news as our abstract has been accepted to #ASCO24 ☺️👏🏼
✔️ TTB as a tool to quantify #AEs in early clinical trials
🙏🏼Thanks to Dr. Rodon and David S. Hong MD for their support MD Anderson Cancer Center
#earlydrugdevelopment #oncology
Vall d’Hebron Institute of Oncology (VHIO)

💥 Night out with the #phaseI team Vall d’Hebron Institute of Oncology (VHIO) 💥
#drugdevelopment

📢 First part of the thesis is out🤩 BJS
👉🏼 Prognostic tool to better select #mCCR patients for adj treat
💥 New Prognostic Tool #HICAM
👉🏼 20 vs 8m #PFS & 105 vs 30m #OS between low and high #risk
✔️ Hepatic metastases
✔️ Colorectal cancer patients
tuit.cat/4b0FC

👏🏼 Un èxit com cada any!👏🏼
Una de les jornades més boniques i útils pel futur dels #MIR Col·legi Metges BCN MetgesjovesCOMB
🎉 Felicitats a la junta Mar de Pablo Miró Marc Patricio I tot staff del col•legi
#OrientacióMIR #JornadesMIR

🗓️3 d'abril, 18 h➡️El Grup de Treball #SalutSenseLlar promogut pel CoMB presenta el document 📃'Propostes per oferir una millor atenció sanitària a les persones sense llar'🏠

📍Sala d'Actes del CoMB
✍️Inscripcions👉i.mtr.cool/yiubihqnyz

Us hi esperem!

🤩 Outstanding news for #UC patients
✔️New standard of care for #urothelial cancer
💪🏼Once again #ADC and #immunotherapy striking #Cancer

📌 Los MIR llegan al Parlament: 'Necesitamos un tope de 48 horas semanales'

➡️ Representantes de la Secció de Metges Joves del CoMB trasladan sus preocupaciones a los diputados catalanes

buff.ly/3wAkoAK

Molt important la compareixença de les seccions joves de Col·legi de Periodistes de Catalunya i Col·legi Metges BCN per explicar la seva situació professional. Es pot resumir amb una alta exigència per formar-se i una gran precarietat laboral posterior. Molta feina a fer. Gràcies pel testimoni.

🤩 Thanks for standing out our work on 'Long-term #survivors in #ECT ' @vhio at the #ESMODailyReporter
#ESMOTAT24 ESMO - Eur. Oncology

#ESMOTAT24
Dosage and combination in #ECT #drugdevelopment
✔️ Study design Pavel Mozgunov
✔️ OPTIMUS project by FDA Dr. Sara
✔️ Practical approaches to dose optimization Dr. Symeonides
✔️ Role of pharmacogenomics George Patrinos
#research #oncokogy ESMO - Eur. Oncology ASCO

💥 What's new on antibody-drug conjugates #ADC 💥
#ESMOTAT24
🗣️ Dr. Kagari 'Next generation #ADC '
🗣️ Barbara Pistilli 'Tumor agnostic ADC'
🗣️ Toshio Shimizu 'Optimizing safety #ADC '
🗣️ G Curigliano MD PhD 'Combos of #ADC '
👏🏼 Interesting panel on the future of #ADC ESMO - Eur. Oncology ASCO SEOM

📢Heu fet l’examen MIR i esteu a punt de triar plaça? No us perdeu la jornada #OrientacioMIR !

➡️Hi trobareu gairebé 100 informadors residents en actiu que us ajudaran a aclarir els dubtes que tingueu✅

🗓️18 de març, 15.30 h
📍CoMB
✍️Inscripcions obertes👉i.mtr.cool/cfmyetcbva

It's been great joining the running team ESMO - Eur. Oncology #ESMOTAT24
👉🏼 Next in Barcelona? #ESMO24

#ESMOTAT24
💥 Prognostic scores for better patient selection in phase I #clinicaltrials
🤩 Excited to present our work from #phaseI Vall d’Hebron Institute of Oncology (VHIO)
🎉 Congratulations to all speakers
🗣️Excellent discussion Dr. Carter The Christie NHS
Thank you all for coming and to all the #VHIO #teamwork

#ESMOTAT24
⚠️ Challenges and opportunities of the European Union IVD #regulations
🪑 FabriceAndre Dr. Britten
👉🏼 Pharma view by Céline Bourguinon
👉🏼 Impact on #phaseI Elena Garralda
👉🏼 Regulator's view Steve Elem
#EU ESMO - Eur. Oncology European Commission
👇🏼LINK
eur-lex.europa.eu/eli/reg/2017/7…

#ESMOTAT24
Surrogate endpoints 🎯 in #ECT
🪑 Elena Garralda Solange Peters
🩸 ctDNA guide decision making Diana Merino Vega
💥 pCR and PFS/OS Solange Peters
💉 MDR by Dr. Rossi IOR cancer research
🔬On-treatment biopsies Paolo Nuciforo
👏🏼 Great talks
#Oncology #research #drugdevelopment

#ESMOTAT24
🩸ctDNA applications 🩸
👉🏼 Marlene Thomas on strengths and weaknesses of #ctDNA Roche
👉🏼 Umberto Malapelle on #MRD
👉🏼 Sandi on Implementing broad panel in @NHS
👉🏼 Dr. SW Tan on #ctDNA in #ECT #drugdevelopment National Cancer Centre Singapore

#ESMOTAT24
💥 Keynote lecture on #neoantigens for response to #IO
🗣️ yardena samuels Weizmann Institute
Targeting translation machinery to increase immunogenicity
#drugdevelopment #Oncology #research ESMO - Eur. Oncology

#ESMOTAT24
🗣️ Dr. Baldini Gustave Roussy discussed:
🦠 Adenovirus vector iv Phase I escalation/ Dr. Khalil
🧬 IL-12-L19 Phase I escalation G Curigliano MD PhD
#drugdevelopment #oncology #phaseI

#ESMOTAT24
Chaired by Elena Garralda Lillian Siu Anastasios Stathis
🤩 Outstanding keynote lecture Dr. Meric-Brenstman MD Anderson Cancer Center
🗣️ Implementing 🎯 #oncology : From genomics to ADCs
🔬Expression target levels
🧬 Payload
📝Tumor type
#drugdevelopment #oncology #research #ADC